

[Nirmatrelvir copackaged with Ritonavir \(Paxlovid\) Information for Prescribers](#)

Paxlovid is ritonavir-boosted nirmatrelvir. Nirmatrelvir is a SARS-CoV-2 protease inhibitor. Paxlovid is available under Emergency Use Authorization (EUA) for treatment of patients with a positive test for SARS-CoV-2 and mild-moderate COVID-19 who are **within 5 days of symptom onset** (date of symptom onset = day 0) and at high risk of progression to severe disease. Patients must be ≥ 12 years old and ≥ 40 kg. For more information, please see the [Fact Sheet for Healthcare Providers – Emergency Use Authorization of Paxlovid](#). Every patient should also receive the [Paxlovid Fact Sheet for Patients, Parents, and Caregivers](#) with their prescription, which should be reviewed with the patient by the prescribing clinician.

	GFR ≥ 60ml/min	GFR 30 - 59ml/min
Dose* (5 day duration)	300mg/100 mg BID	150mg/100 mg BID

* Dose is expressed in mg of nirmatrelvir/mg ritonavir

Contraindications:

1. Not recommended for patients who have severe hepatic impairment (Child-Pugh Class C)
2. Not recommended in patients with GFR < 30ml/min
3. In patients with uncontrolled or undiagnosed HIV infection, there is a theoretical risk of selection for HIV-1 resistance to protease inhibitors

Instructions for Prescription:

Paxlovid consists of 2 medicines: nirmatrelvir and ritonavir copackaged into 5 blister packs, 1 for each day of treatment. Instructions to include on the prescription are:

- For GFR > 60ml/min: *“3 tabs by mouth twice a day. Take 2 pink tabs with 1 white tab by mouth twice daily for 5 days. Take all 3 tabs at once for each dose.”*
- For GFR 30-59ml/min: *“2 tabs by mouth twice a day. Take 1 pink tab with 1 white tab by mouth twice daily for 5 days. Take both tabs together for each dose.”*
- Pink tabs = nirmatrelvir, White tabs = ritonavir
- When dose adjustment is required (eGFR <60ml/min), paxlovid will be dispensed in appropriate renally-adjusted packaging.

Additional instructions for how patients should take Paxlovid are available [here](#).

Drug-Drug Interactions:

Due to the risk for clinically significant Drug-Drug Interactions, BILH is utilizing the [NIH guidance on medications](#) that categorize drug-drug interactions into three categories: absolute contraindication (prescribe alternate COVID therapy), temporarily hold therapy, or adjust concomitant medication dose and monitor. This list is not exhaustive. Please consult the [Liverpool COVID 19 drug interaction website](#) for more details, or to check additional drug-drug interactions.

For more details around management of anticoagulant drug interactions please [refer to this document](#):